Esperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Esperion Therapeutics (NASDAQ:ESPR) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.06), FiscalAI reports. The company had revenue of $80.10 million during the quarter, compared to the consensus estimate of $84.52 million.

Esperion Therapeutics Stock Performance

ESPR remained flat at $3.14 on Friday. 7,427,546 shares of the company traded hands, compared to its average volume of 20,251,564. The stock has a market cap of $808.24 million, a price-to-earnings ratio of -18.47, a P/E/G ratio of 2.55 and a beta of 0.91. The stock’s 50-day simple moving average is $2.53 and its two-hundred day simple moving average is $3.09. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Needham & Company LLC cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Jefferies Financial Group cut Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Citizens Jmp downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.54.

Institutional Trading of Esperion Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new position in Esperion Therapeutics during the fourth quarter worth $70,000. Invesco Ltd. grew its stake in shares of Esperion Therapeutics by 23.5% in the fourth quarter. Invesco Ltd. now owns 765,118 shares of the biopharmaceutical company’s stock valued at $2,831,000 after buying an additional 145,351 shares in the last quarter. Mackenzie Financial Corp raised its holdings in shares of Esperion Therapeutics by 23.5% in the 4th quarter. Mackenzie Financial Corp now owns 336,992 shares of the biopharmaceutical company’s stock valued at $1,241,000 after buying an additional 64,034 shares during the period. XTX Topco Ltd acquired a new position in Esperion Therapeutics during the 4th quarter worth about $599,000. Finally, nVerses Capital LLC acquired a new position in Esperion Therapeutics during the 4th quarter worth about $250,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.